Impact of VEGF Levels on Colorectal Cancer Survival
Author Information
Author(s): Werther K, Christensen I J, Nielsen H J
Primary Institution: Hvidovre University Hospital, University of Copenhagen
Hypothesis
Is preoperative serum or plasma VEGF a better predictor of survival in colorectal cancer patients?
Conclusion
Preoperative serum VEGF is a better predictor of overall survival than plasma VEGF in colorectal cancer patients.
Supporting Evidence
- Plasma VEGF levels were significantly higher in colorectal cancer patients compared to healthy donors.
- High serum VEGF levels independently predicted reduced survival in colon cancer patients.
- No significant difference in serum VEGF levels was found between colorectal cancer patients and healthy donors.
Takeaway
This study found that measuring a substance called VEGF in the blood can help doctors understand how long patients with colorectal cancer might live after surgery.
Methodology
The study analyzed VEGF levels in plasma and serum from 524 colorectal cancer patients and 50 healthy donors, comparing their prognostic value.
Potential Biases
Potential bias due to the reliance on blood samples and the effects of platelet degranulation.
Limitations
The study may not account for all factors influencing VEGF levels and survival.
Participant Demographics
Patients included 316 men and 208 women, median age 69 years; healthy donors were 30 men and 20 women, median age 59 years.
Statistical Information
P-Value
0.015
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website